10068 Results for "

activate

" in MedChemExpress (MCE) Product Catalog:
Products (10068)

10068 Results for "activate" in MCE Product Catalog:

Cat. No.: HY-N7773
CAS No.: 577-24-2
Hibiscetin is an orally active anti-inflammatory, antioxidant, antihyperglycemic, hypolipidemic, hepatoprotective and neuroprotective agent. Hibiscetin reduces the levels of TNF-α, IL-1β and IL-6. Hibiscetin inhibits lipid peroxidation, reduces MDA levels, and induces the activities of antioxidant enzymes CAT, GSH and SOD. Hibiscetin lowers blood glucose, reverses reduced insulin levels, regulates adipokine levels, and reduces elevated AST and ALT levels. Hibiscetin alleviates Rotenone (HY-B1756)-induced akinesia and catalepsy, normalizes neurotransmitter levels, and modulates the activities of activated caspase 3 and BDNF. Hibiscetin can be used in the research of type 2 diabetes, Parkinson's disease and Huntington's disease .
loading...
    loading...
Cat. No.: HY-N8210R
CAS No.: 446-71-9
Homoeriodictyol (Standard) is the analytical standard of Homoeriodictyol (HY-N8210). This product is intended for research and analytical applications. Homoeriodictyol is an orally active, bitter-tasting flavanone that can penetrate the blood-brain barrier. Homoeriodictyol enhances synaptic-related protein expression through NCOA4-mediated ferritin autophagy. Homoeriodictyol improves memory impairment in mice by inhibiting the NLRP3 inflammasome. Homoeriodictyol protects human endothelial cells from oxidative damage by activating Nrf2 and inhibiting mitochondrial dysfunction. Homoeriodictyol enhances ROS activity and induces apoptosis, exhibiting anticancer effects. Homoeriodictyol inhibits the survival and migration of androgen-resistant prostate cancer cells in vitro. Homoeriodictyol exerts antinociceptive activity in mice in vivo .
loading...
    loading...
Cat. No.: HY-N8852
CAS No.: 3034-04-6
Synonyms: 6-MeOF
6-Methoxyflavanone (6-MeOF) is a flavonoid compound that can cross the blood-brain barrier. 6-Methoxyflavanone is a positive allosteric modulator of GABAA receptors. 6-Methoxyflavanone exhibits positive allosteric regulatory effects on human recombinant α1β2γ2L and α2β2γ2L GABAA receptors, and is relatively inactive on the α1β2 GABAA receptor. 6-Methoxyflavanone showes inhibitory behavior towards the activation of bitter receptor hTAS2R39 and hTAS2R14, demonstrating a reversible and non-overcome antagonistic effect. 6-Methoxyflavanone has the effects of anti-anxiety, analgesia and relief of neuropathic pain .
loading...
    loading...
Cat. No.: HY-NP0204
Synonyms: Mouse Serum Albumin
MSA Protein (Mouse Serum Albumin) is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .
loading...
    loading...
Cat. No.: HY-P10371
CAS No.: 1505523-99-8
Synonyms: txCD47
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8 + T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .
loading...
    loading...
Cat. No.: HY-P10495
CAS No.: 1778685-49-6
Research Areas:  

Others Cancer

GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110 .
loading...
    loading...
Cat. No.: HY-P10580
CAS No.: 1359657-45-6
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury .
loading...
    loading...
Cat. No.: HY-P10580A
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury .
loading...
    loading...
Cat. No.: HY-P10638
Target:  

CaMK

TAT-CN21 is a potent CaMKII inhibitor with an IC50 of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .
loading...
    loading...
Cat. No.: HY-P10966A
Target:  

IKK NF-κB

Research Areas:  

Inflammation/Immunology

Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60) (HY-P10966). Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P11220
Research Areas:  

Infection

Hs02 is a cationic amphiphilic antibacterial peptide derived from human proteins, and it is the membrane-active module of the core chimeric peptide Chim2. Hs02 exhibits broad-spectrum and potent antibacterial activity against various human pathogenic bacteria with the MIC for Staphylococcus aureus and Escherichia coli of as low as 2 μM, and the MBC is 2-4 μM. Hs02 primarily kills bacteria by disrupting the integrity of the bacterial cell membrane, and it has a relatively low selectivity for eukaryotic cell membranes. Hs02 induces the release of IL-12 but does not induce the release of IL-6, indicating its potential for pro-inflammatory or immune activation. Hs02 can be used in antibacterial and immunomodulatory research .
loading...
    loading...
Cat. No.: HY-P11246
CAS No.: 3057097-31-8
Target:  

RXFP Receptor

Research Areas:  

Metabolic Disease

A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
loading...
    loading...
Cat. No.: HY-P11467
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .
loading...
    loading...
Cat. No.: HY-P11887
CAS No.: 1174559-81-9
VHPKQHR is a peptide-based delivery enhancer that binds to VCAM-1. VHPKQHR enables intracellular internalization of relevant nanomaterials and facilitates the targeted delivery of miRNA inhibitors to inflamed endothelial cells and endothelial cells activated by disturbed flow. When conjugated with magnetic mesoporous silica nanoparticles, VHPKQHR achieves targeted accumulation at atherosclerotic plaque sites. When displayed on the surface of polyelectrolyte complex micelles, VHPKQHR enhances the relevant effects of anti-miR-92a in Apoe -/- mice. When conjugated with ultrasmall superparamagnetic iron oxide nanoparticles, VHPKQHR forms a contrast agent for T1-weighted magnetic resonance imaging. VHPKQHR can be used in research related to atherosclerosis, stenosis and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P11902
Research Areas:  

Cancer

IRS1 is an integrin-targeted, ROS-responsive self-assembling peptide prodrug molecule with selective anti-cancer activity against integrin-overexpressing tumor cells. IRS1 contains an RGD motif for integrin binding, can covalently bind to DR4/DR5, and promotes DR4/DR5 aggregation. After oxidation by ROS, IRS1 undergoes a morphological transition from nanoparticles to nanofibers, exposes the pharmacophore of Chlorambucil (HY-13593), disrupts cell membrane integrity, activates the extrinsic apoptosis pathway, and can penetrate and inhibit the three-dimensional uveal melanoma spheroid model. IRS1 can be used for the research of uveal melanoma .
loading...
    loading...
Cat. No.: HY-P1221A
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

ProTx II TFA is a selective blocker of Nav1.7 sodium channels, with an IC50 value of 0.3 nM and a Ki of 0.389 nM against human NaV1.7. ProTx II TFA selectively blocks spinal cord NaV1.7 by reducing conductance and altering voltage dependence of activation, preferentially binds to the splice region of aNaV1.5, and can also block sodium channel subtypes such as Nav1.4 and Nav1.6. ProTx II TFA alleviates thermal hyperalgesia in diabetic mice and prevents the propagation of action potentials in nociceptors. ProTx II TFA can be used for research related to painful diabetic neuropathy and pain disorders .
loading...
    loading...
Cat. No.: HY-P2200
CAS No.: 164802-68-0
Synonyms: BMY-29304
Target:  

HIV Antibiotic

Research Areas:  

Infection Inflammation/Immunology

Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .
loading...
    loading...
Cat. No.: HY-P2819
CAS No.: 9001-80-3
Synonyms: PFK1
Phosphofructokinase 1 (PFK1) is a glycolytic enzyme and also an allosteric activation target of fructose-2,6-bisphosphate. PFK1 supports cardiac glycolysis to maintain normal cardiac function and mediates adaptive responses to pressure overload. Upregulated expression and activity of PFK1 are associated with the alleviation of pathological changes induced by pressure overload, including diastolic dysfunction, interstitial fibrosis and myocardial hypertrophy. Inhibition of PFK1 redirects glucose carbon flux to the pentose phosphate pathway. PFK1 promotes proliferation, migration and glycolysis of colorectal cancer cells, reduces apoptosis and decreases their radiosensitivity, and shows higher expression levels in radioresistant tumors. PFK1 can be used in research related to diastolic dysfunction heart failure and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P2819A
CAS No.: 9001-80-3
Phosphofructokinase,Bacillus stearothermophilus is a glycolytic enzyme and also an allosteric activation target of fructose-2,6-bisphosphate. PFK1 supports cardiac glycolysis to maintain normal cardiac function and mediates adaptive responses to pressure overload. Upregulated expression and activity of PFK1 are associated with the alleviation of pathological changes induced by pressure overload, including diastolic dysfunction, interstitial fibrosis and myocardial hypertrophy. Inhibition of PFK1 redirects glucose carbon flux to the pentose phosphate pathway. PFK1 promotes proliferation, migration and glycolysis of colorectal cancer cells, reduces apoptosis and decreases their radiosensitivity, and shows higher expression levels in radioresistant tumors. PFK1 can be used in research related to diastolic dysfunction heart failure and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P4121
CAS No.: 1898254-09-5
Target:  

Potassium Channel

Research Areas:  

Inflammation/Immunology Cancer

L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide that can be used to deliver a variety of macromolecules, including proteins, antibodies, and DNA nanostructures. L17E inserts and cleaves the membrane structure through electrostatic interaction, enabling intracellular escape. The efficiency of L17E-mediated delivery is strongly correlated with the expression level of KCNN4 (the gene encoding the calcium-activated potassium channel KCa3.1). L17E also promotes the cellular uptake of macromolecules by inducing micropinocytosis. L17E can be further optimized and improved through dimerization strategies and in combination with other delivery systems, such as nuclear localization signal peptides and cell membrane-coated nanoparticles .
loading...
    loading...